CVRX
CVRx, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
CVRx, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Feb 13 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 13 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−59.76%
vs ±51.8% implied · ×1.15
shaded = implied · ▲▼ = realized
CVRx, Inc.
1.49
+0.11 · +7.99%
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of CVRx, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: Stryker Corp, 3M Co, Boston Scientific Corp and 3 more; of CVRx, Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Johnson & Johnson | $20.7M | 26.29% | 0.00% |
| NEA | $10.0M | 12.77% | −3.54% |
| BlackRockindex-like | $6.4M | 8.13% | +21.32% |
| Royal Bank of Canada | $6.3M | 8.05% | +74.44% |
| Glaxosmithkline | $5.2M | 6.58% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Johnson & Johnson | $20.7M | 26.29% | 0.00% |
| NEA | $10.0M | 12.77% | −3.54% |
| BlackRockindex-like | $6.4M | 8.13% | +21.32% |
| Royal Bank of Canada | $6.3M | 8.05% | +74.44% |
| Glaxosmithkline | $5.2M | 6.58% | 0.00% |
Bull1
Bear2
Expected move
Inputsspot 1.37exp Nov 20ATM strike 2.5ATM straddle 1.28IV 252%